Cefepime and mortality: A real issue?Cefepime and mortality: A real issue?
Faculty of Medicine and Health Sciences
Vaccine & Infectious Disease Institute (VAXINFECTIO)
Scandinavian journal of infectious diseases. - Stockholm
42(2010):6-7, p. 545-548
University of Antwerp
The fourth-generation cephalosporin, cefepime, has an antimicrobial spectrum that makes it a valuable antibiotic for empirical treatment of neutropenic fever. Randomized trials have proven the efficacy and safety of cefepime in neutropenic fever. However, 2 recent meta-analyses have shown an increased all-cause mortality for cefepime. Since then, many clinicians have been left in doubt about the use of cefepime for this indication. In this paper, we put in perspective some of the methodological and clinical issues and call for further clinical analyses.